{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:31:44Z","timestamp":1787067104567,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s11912-023-01360-1","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T03:02:35Z","timestamp":1674615755000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Nectin-4: a Tumor Cell Target and Status of Inhibitor Development"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-9386","authenticated-orcid":false,"given":"Wafa","family":"Bouleftour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Magne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"1360_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","volume":"18","author":"EI Heath","year":"2021","unstructured":"Heath EI, Rosenberg JE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol. 2021;18:93\u2013103.","journal-title":"Nat Rev Urol"},{"key":"1360_CR2","unstructured":"Research C for DE and. FDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancer. FDA [Internet]. FDA; 2019 [cited 2022 Sep 28]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-enfortumab-vedotin-ejfv-metastatic-urothelial-cancer"},{"key":"1360_CR3","doi-asserted-by":"publisher","first-page":"27006","DOI":"10.1074\/jbc.M203228200","volume":"277","author":"S Fabre","year":"2002","unstructured":"Fabre S, Reymond N, Cocchi F, Menotti L, Dubreuil P, Campadelli-Fiume G, et al. Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin 4 bind to the predicted C-C\u2019-C\"-D beta-strands of the nectin1 V domain. J Biol Chem. 2002;277:27006\u201313.","journal-title":"J Biol Chem"},{"key":"1360_CR4","doi-asserted-by":"publisher","first-page":"43205","DOI":"10.1074\/jbc.M103810200","volume":"276","author":"N Reymond","year":"2001","unstructured":"Reymond N, Fabre S, Lecocq E, Adela\u00efde J, Dubreuil P, Lopez M. Nectin4\/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1\/PRR1 through V domain interaction. J Biol Chem. 2001;276:43205\u201315.","journal-title":"J Biol Chem"},{"key":"1360_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1309\/AJCPGXK0FR4MHIHB","volume":"134","author":"MS DeRycke","year":"2010","unstructured":"DeRycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, et al. Nectin 4 overexpression in ovarian cancer tissues and serum. Am J Clin Pathol. 2010;134:835\u201345.","journal-title":"Am J Clin Pathol"},{"key":"1360_CR6","doi-asserted-by":"publisher","first-page":"6694","DOI":"10.1158\/0008-5472.CAN-09-0016","volume":"69","author":"A Takano","year":"2009","unstructured":"Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 2009;69:6694\u2013703.","journal-title":"Cancer Res"},{"key":"1360_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1471-2407-7-73","volume":"7","author":"S Fabre-Lafay","year":"2007","unstructured":"Fabre-Lafay S, Monville F, Garrido-Urbani S, Berruyer-Pouyet C, Ginestier C, Reymond N, et al. Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer. 2007;7:73.","journal-title":"BMC Cancer"},{"key":"1360_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12935-019-0824-z","volume":"19","author":"H Deng","year":"2019","unstructured":"Deng H, Shi H, Chen L, Zhou Y, Jiang J. Over-expression of Nectin-4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients. Cancer Cell Int. 2019;19:106.","journal-title":"Cancer Cell Int"},{"key":"1360_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13046-015-0144-7","volume":"34","author":"S Nishiwada","year":"2015","unstructured":"Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, et al. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res. 2015;34:30.","journal-title":"J Exp Clin Cancer Res"},{"key":"1360_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","volume":"21","author":"W Bouleftour","year":"2022","unstructured":"Bouleftour W, Guillot A, Magne N. The Anti-Nectin 4: a promising tumor cells target A systematic review. Mol Cancer Ther. 2022;21:493\u2013501.","journal-title":"Mol Cancer Ther"},{"key":"1360_CR11","doi-asserted-by":"crossref","unstructured":"\u2022 Tanaka Y, Murata M, Tanegashima K, Oda Y, Ito T. Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma. Sci Rep. 2022;12:4031. This study reported for the first time an expression of Nectin-4 in angiosarcoma and the regulation of angiogenesis by Nectin-4 through Src signaling pathway.","DOI":"10.1038\/s41598-022-07727-x"},{"key":"1360_CR12","doi-asserted-by":"crossref","unstructured":"\u2022 Liu Y, Li G, Zhang Y, Li L, Zhang Y, Huang X, et al. Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K\/AKT\/NF-\u03baB signaling by down-regulation of miR-520c-3p. Cancer Cell Int. 2022;22:252. This study reported for the first time an upregulation of Nectin-4 is osteosarcoma and the down regulation of miR-520c-3p involved in tumor progression and metastasis.","DOI":"10.1186\/s12935-022-02669-w"},{"key":"1360_CR13","doi-asserted-by":"crossref","unstructured":"\u2022 Toda S, Sato S, Saito N, Sekihara K, Matsui A, Murayama D, et al. TROP-2, Nectin-4, GPNMB, and B7-H3 are potentially therapeutic targets for anaplastic thyroid carcinoma. Cancers (Basel). 2022;14:579. This study demonstrated Nectin-4 increased expression in de novo anaplastic thyroid carcinoma.","DOI":"10.3390\/cancers14030579"},{"key":"1360_CR14","doi-asserted-by":"crossref","unstructured":"\u2022 Hao R-T, Zheng C, Wu C-Y, Xia E-J, Zhou X-F, Quan R-D, et al. NECTIN4 promotes papillary thyroid cancer cell proliferation, migration, and invasion and triggers EMT by activating AKT. Cancer Manag Res. 2019;11:2565\u201378. This study reported the pathway explaining the role of Nectin-4 in in proliferation, migration and invasion of papillary thyroid cancer cells.","DOI":"10.2147\/CMAR.S190332"},{"key":"1360_CR15","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1074\/jbc.M116.746859","volume":"292","author":"PC Buchanan","year":"2017","unstructured":"Buchanan PC, Boylan KLM, Walcheck B, Heinze R, Geller MA, Argenta PA, et al. Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17. J Biol Chem. 2017;292:6339\u201351.","journal-title":"J Biol Chem"},{"key":"1360_CR16","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6:1769\u201392.","journal-title":"Cancers (Basel)"},{"key":"1360_CR17","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","volume":"15","author":"F Loganzo","year":"2016","unstructured":"Loganzo F, Sung M, Gerber H-P. Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther. 2016;15:2825\u201334.","journal-title":"Mol Cancer Ther"},{"key":"1360_CR18","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Hoffman-Censits JH, Lombardo KA, Parimi V, Kamanda S, Choi W, Hahn NM, et al. Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes. Appl Immunohistochem Mol Morphol. 2021. This study demonstrated Nectin-4 heterogeneity in urothelial carcinoma. Nectin-4 expression could be a marker for patient selection and enfortumab vedotin sensitivity.","DOI":"10.1097\/PAI.0000000000000938"},{"key":"1360_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.canlet.2016.02.049","volume":"375","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Liu S, Wang L, Wu Y, Hao J, Wang Z, et al. A novel PI3K\/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth. Cancer Lett. 2016;375:179\u201389.","journal-title":"Cancer Lett"},{"key":"1360_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.humpath.2017.10.034","volume":"72","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Chen P, Yin W, Ji Y, Shen Q, Ni Q. Nectin-4 promotes gastric cancer progression via the PI3K\/AKT signaling pathway. Hum Pathol. 2018;72:107\u201316.","journal-title":"Hum Pathol"},{"key":"1360_CR21","doi-asserted-by":"publisher","first-page":"e00358","DOI":"10.7554\/eLife.00358","volume":"2","author":"NN Pavlova","year":"2013","unstructured":"Pavlova NN, Pallasch C, Elia AEH, Braun CJ, Westbrook TF, Hemann M, et al. A role for PVRL4-driven cell-cell interactions in tumorigenesis. Elife. 2013;2:e00358.","journal-title":"Elife"},{"key":"1360_CR22","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1111\/cas.14344","volume":"111","author":"L Wang","year":"2020","unstructured":"Wang L, Yang M, Guo X, Yang Z, Liu S, Ji Y, et al. Estrogen-related receptor-\u03b1 promotes gallbladder cancer development by enhancing the transcription of Nectin-4. Cancer Sci. 2020;111:1514\u201327.","journal-title":"Cancer Sci"},{"key":"1360_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.biocel.2017.06.007","volume":"89","author":"S Siddharth","year":"2017","unstructured":"Siddharth S, Goutam K, Das S, Nayak A, Nayak D, Sethy C, et al. Nectin-4 is a breast cancer stem cell marker that induces WNT\/\u03b2-catenin signaling via Pi3k\/Akt axis. Int J Biochem Cell Biol. 2017;89:85\u201394.","journal-title":"Int J Biochem Cell Biol"},{"key":"1360_CR24","doi-asserted-by":"publisher","first-page":"7344","DOI":"10.1038\/s41598-021-86437-2","volume":"11","author":"S Kedashiro","year":"2021","unstructured":"Kedashiro S, Kameyama T, Mizutani K, Takai Y. Nectin-4 and p95-ErbB2 cooperatively regulate Hippo signaling-dependent SOX2 gene expression, enhancing anchorage-independent T47D cell proliferation. Sci Rep. 2021;11:7344.","journal-title":"Sci Rep"},{"key":"1360_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.biocel.2018.07.011","volume":"102","author":"S Siddharth","year":"2018","unstructured":"Siddharth S, Nayak A, Das S, Nayak D, Panda J, Wyatt MD, et al. The soluble nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial Integrin-\u03b24. Int J Biochem Cell Biol. 2018;102:151\u201360.","journal-title":"Int J Biochem Cell Biol"},{"key":"1360_CR26","doi-asserted-by":"publisher","first-page":"173308","DOI":"10.1016\/j.ejphar.2020.173308","volume":"883","author":"S Chatterjee","year":"2020","unstructured":"Chatterjee S, Kundu CN. Nanoformulated quinacrine regulates NECTIN-4 domain specific functions in cervical cancer stem cells. Eur J Pharmacol. 2020;883:173308.","journal-title":"Eur J Pharmacol"},{"key":"1360_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s13402-018-0417-1","volume":"42","author":"A Nayak","year":"2019","unstructured":"Nayak A, Das S, Nayak D, Sethy C, Narayan S, Kundu CN. Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation. Cell Oncol (Dordr). 2019;42:157\u201371.","journal-title":"Cell Oncol (Dordr)"},{"key":"1360_CR28","doi-asserted-by":"publisher","first-page":"109902","DOI":"10.1016\/j.cellsig.2020.109902","volume":"80","author":"S Chatterjee","year":"2021","unstructured":"Chatterjee S, Sinha S, Molla S, Hembram KC, Kundu CN. PARP inhibitor Veliparib (ABT-888) enhances the anti-angiogenic potentiality of Curcumin through deregulation of NECTIN-4 in oral cancer: role of nitric oxide (NO). Cell Signal. 2021;80:109902.","journal-title":"Cell Signal"},{"key":"1360_CR29","doi-asserted-by":"crossref","unstructured":"Sethy C, Goutam K, Das B, Dash SR, Kundu CN. Nectin-4 promotes lymphangiogenesis and lymphatic metastasis in breast cancer by regulating CXCR4-LYVE-1 axis. Vascul Pharmacol. 2021;106865.","DOI":"10.1016\/j.vph.2021.106865"},{"key":"1360_CR30","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg JE, O\u2019Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy. J Clin Oncol. 2019;37:2592\u2013600.","journal-title":"J Clin Oncol"},{"key":"1360_CR31","first-page":"394","volume":"39","author":"AV Balar","year":"2021","unstructured":"Balar AV, McGregor BA, Rosenberg JE, Van Der Heijden MS, Park SH, Lee J-L, et al. EV-201 Cohort 2: enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1\/PD-L1 inhibitors. JCO Wolters Kluwer. 2021;39:394\u2013394.","journal-title":"JCO Wolters Kluwer"},{"key":"1360_CR32","doi-asserted-by":"publisher","unstructured":"Matsubara N, Yonese J, Kojima T, Azuma H, Matsumoto H, Powles T, et al. Japanese subgroup analysis of EV-301: an open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Med. 2022.\u00a0https:\/\/doi.org\/10.1002\/cam4.5165.","DOI":"10.1002\/cam4.5165"},{"key":"1360_CR33","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee J-L, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125\u201335.","journal-title":"N Engl J Med"},{"key":"1360_CR34","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Chu CE, Sj\u00f6str\u00f6m M, Egusa EA, Gibb EA, Badura ML, Zhu J, et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin Cancer Res. 2021;clincanres.4175.2020. This study demonstrated Nectin-4 heterogeneity in urothelial carcinoma. Nectin-4 expression could be a marker for patient selection and enfortumab vedotin sensitivity.","DOI":"10.1200\/JCO.2021.39.6_suppl.463"},{"key":"1360_CR35","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Garczyk S, Degener S, Bischoff F, Schnitzler T, Salz A, Golz R, et al. Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer. Virchows Arch. 2022;481:83\u201392. This study demonstrated Nectin-4 heterogeneity in high-grade non-muscle-invasive bladder cancer, which is a population with limited treatment option.","DOI":"10.1007\/s00428-022-03328-1"},{"key":"1360_CR36","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Cabaud O, Berger L, Crompot E, Ad\u00e9laide J, Finetti P, Garnier S, et al. Overcoming resistance to anti-Nectin-4 antibody-drug conjugate. Mol Cancer Ther. 2022;21:1227\u201335. The first study investigating the mechanism of Enfortumab Vedotin resistance through a an elegant preclinical model.","DOI":"10.1158\/1535-7163.MCT-22-0013"},{"key":"1360_CR37","doi-asserted-by":"publisher","first-page":"E5390","DOI":"10.3390\/ijms21155390","volume":"21","author":"E Tomiyama","year":"2020","unstructured":"Tomiyama E, Fujita K, Rodriguez Pena MDC, Taheri D, Banno E, Kato T, et al. Expression of Nectin-4 and PD-L1 in upper tract urothelial carcinoma. Int J Mol Sci. 2020;21:E5390.","journal-title":"Int J Mol Sci"},{"key":"1360_CR38","doi-asserted-by":"publisher","first-page":"e25806","DOI":"10.1371\/journal.pone.0025806","volume":"6","author":"H El-Osta","year":"2011","unstructured":"El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, et al. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One. 2011;6:e25806.","journal-title":"PLoS One"},{"key":"1360_CR39","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3390\/ijms22020976","volume":"22","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Murata M, Shen C-H, Furue M, Ito T. NECTIN4: a novel therapeutic target for melanoma. Int J Mol Sci. 2021;22:976.","journal-title":"Int J Mol Sci"},{"key":"1360_CR40","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4103\/0971-5916.159250","volume":"141","author":"PK Jaiswal","year":"2015","unstructured":"Jaiswal PK, Goel A, Mittal RD. Survivin: a molecular biomarker in cancer. Indian J Med Res. 2015;141:389\u201397.","journal-title":"Indian J Med Res"},{"key":"1360_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5603\/FHC.2011.0005","volume":"49","author":"AM Athanassiadou","year":"2011","unstructured":"Athanassiadou AM, Patsouris E, Tsipis A, Gonidi M, Athanassiadou P. The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma. Folia Histochem Cytobiol. 2011;49:26\u201333.","journal-title":"Folia Histochem Cytobiol"},{"key":"1360_CR42","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1007\/s00432-021-03622-6","volume":"147","author":"P Li","year":"2021","unstructured":"Li P, Hou F, Wang S, Luo N, Qi Y, Wang Y. A novel NECTIN4-NTRK1 fusion identified in a lung squamous cell carcinoma patient with MSI-H. J Cancer Res Clin Oncol. 2021;147:2483\u20136.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1360_CR43","doi-asserted-by":"crossref","unstructured":"\u2022 Calandrella ML, Francesconi S, Caprera C, Mosillo C, Caserta C, Giannarelli D, et al. Nectin-4 and DNA mismatch repair proteins expression in upper urinary tract urothelial carcinoma (UTUC) as a model for tumor targeting approaches: an ImGO pilot study. BMC Cancer. 2022;22:168. This pilot study demonstrated a potential correlation between Nectin-4 and DNA MMR, which can be developed as a predictive tool for immunotherapy and Enfortumab Vedotin combination.","DOI":"10.1186\/s12885-022-09259-z"},{"key":"1360_CR44","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s11307-016-0953-x","volume":"18","author":"DO Campbell","year":"2016","unstructured":"Campbell DO, Noda A, Verlinsky A, Snyder J, Fujita Y, Murakami Y, et al. Preclinical evaluation of an anti-Nectin-4 ImmunoPET reagent in tumor-bearing mice and biodistribution studies in cynomolgus monkeys. Mol Imaging Biol. 2016;18:768\u201375.","journal-title":"Mol Imaging Biol"},{"key":"1360_CR45","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12951-022-01444-3","volume":"20","author":"F Shao","year":"2022","unstructured":"Shao F, Pan Z, Long Y, Zhu Z, Wang K, Ji H, et al. Nectin-4-targeted immunoSPECT\/CT imaging and photothermal therapy of triple-negative breast cancer. J Nanobiotechnology. 2022;20:243.","journal-title":"J Nanobiotechnology"},{"key":"1360_CR46","doi-asserted-by":"publisher","first-page":"24572","DOI":"10.1038\/srep24572","volume":"6","author":"Y Amagai","year":"2016","unstructured":"Amagai Y, Fujiyuki T, Yoneda M, Shoji K, Furukawa Y, Sato H, et al. Oncolytic activity of a recombinant measles virus, blind to signaling lymphocyte activation molecule, against colorectal cancer cells. Sci Rep. 2016;6:24572.","journal-title":"Sci Rep"},{"key":"1360_CR47","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1111\/cas.13064","volume":"107","author":"M Awano","year":"2016","unstructured":"Awano M, Fujiyuki T, Shoji K, Amagai Y, Murakami Y, Furukawa Y, et al. Measles virus selectively blind to signaling lymphocyte activity molecule has oncolytic efficacy against nectin-4-expressing pancreatic cancer cells. Cancer Sci. 2016;107:1647\u201352.","journal-title":"Cancer Sci"},{"key":"1360_CR48","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.omto.2020.09.007","volume":"19","author":"T Fujiyuki","year":"2020","unstructured":"Fujiyuki T, Amagai Y, Shoji K, Kuraishi T, Sugai A, Awano M, et al. Recombinant SLAMblind measles virus is a promising candidate for Nectin-4-positive triple negative breast cancer therapy. Mol Ther-Oncolytics Elsevier. 2020;19:127\u201335.","journal-title":"Mol Ther-Oncolytics Elsevier"},{"key":"1360_CR49","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/biomedicines9040355","volume":"9","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Murata M, Oda Y, Furue M, Ito T. Nectin cell adhesion molecule 4 (NECTIN4) expression in cutaneous squamous cell carcinoma: a new therapeutic target? Biomedicines. 2021;9:355.","journal-title":"Biomedicines"},{"key":"1360_CR50","doi-asserted-by":"publisher","first-page":"725","DOI":"10.18632\/oncotarget.28233","volume":"13","author":"P Gulhane","year":"2022","unstructured":"Gulhane P, Nimsarkar P, Kharat K, Singh S. Deciphering miR-520c-3p as a probable target for immunometabolism in non-small cell lung cancer using systems biology approach. Oncotarget. 2022;13:725\u201346.","journal-title":"Oncotarget"},{"key":"1360_CR51","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1111\/febs.14835","volume":"286","author":"X Li","year":"2019","unstructured":"Li X, Fu Q, Li H, Zhu L, Chen W, Ruan T, et al. MicroRNA-520c-3p functions as a novel tumor suppressor in lung adenocarcinoma. FEBS J. 2019;286:2737\u201352.","journal-title":"FEBS J"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01360-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-023-01360-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01360-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T10:23:16Z","timestamp":1701771796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-023-01360-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1360"],"URL":"https:\/\/doi.org\/10.1007\/s11912-023-01360-1","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]},"assertion":[{"value":"30 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}